Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma

NCT04145700 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04145700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04145700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 1/2
Overall status
Terminated
Start date
March 4, 2020
Completion date
February 23, 2023
Enrollment
23 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

synovial sarcoma